IDEXX Laboratories Inc
F:IX1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
IDEXX Laboratories Inc
F:IX1
|
US |
|
D
|
Deutsche Boerse AG
XMUN:DB1
|
DE |
|
Amcor PLC
F:485B
|
UK |
|
L
|
Lattice Semiconductor Corp
SWB:LTT
|
US |
|
A
|
AXA SA
PAR:CSNV
|
FR |
|
I
|
Itochu Corp
XMUN:IOC
|
JP |
|
Beeks Financial Cloud Group PLC
LSE:BKS
|
UK |
|
Bank of Montreal
TSX:BMO
|
CA |
|
Corcept Therapeutics Inc
NASDAQ:CORT
|
US |
|
A
|
AP Thailand PCL
SET:AP
|
TH |
|
Ranpak Holdings Corp
NYSE:PACK
|
US |
Wall St Price Targets
IX1 Price Targets Summary
IDEXX Laboratories Inc
According to Wall Street analysts, the average 1-year price target for IX1 is 639.12 EUR with a low forecast of 406.04 EUR and a high forecast of 731.06 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is IX1's stock price target?
Price Target
639.12
EUR
According to Wall Street analysts, the average 1-year price target for IX1 is 639.12 EUR with a low forecast of 406.04 EUR and a high forecast of 731.06 EUR.
What is the Revenue forecast for IDEXX Laboratories Inc?
Projected CAGR
10%
Over the last 13 years, the compound annual growth rate for Revenue has been 10%. The projected CAGR for the next 8 years is 10%.
What is the Operating Income forecast for IDEXX Laboratories Inc?
Projected CAGR
13%
Over the last 13 years, the compound annual growth rate for Operating Income has been 14%. The projected CAGR for the next 8 years is 13%.
What is the Net Income forecast for IDEXX Laboratories Inc?
Projected CAGR
14%
Over the last 13 years, the compound annual growth rate for Net Income has been 15%. The projected CAGR for the next 8 years is 14%.
